Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$29.09 USD

29.09
308,570

-0.14 (-0.48%)

Updated Nov 13, 2024 02:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why

by Zacks Equity Research

Spectrum Pharmaceuticals (SPPI) stock is witnessing significant momentum mainly on encouraging data from poziotinib study.

    BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

    by Zacks Equity Research

    BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

      Arpita Dutt headshot

      3 Pharma and Biotech Stocks to Watch Out for in 2018

      by Arpita Dutt

      Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

        Allergan's Vraylar Positive for Bipolar Disease in Phase III

        by Zacks Equity Research

        Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.

          Surging Earnings Estimates Signal Good News for Alkermes (ALKS)

          by Zacks Equity Research

          Alkermes (ALKS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

            Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

            by Zacks Equity Research

            The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

              Arpita Dutt headshot

              Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

              by Arpita Dutt

              While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

                Biogen Acquires Worldwide License for Alkermes' MS Candidate

                by Zacks Equity Research

                Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.

                  Why Is Alkermes (ALKS) Down 8.3% Since the Last Earnings Report?

                  by Zacks Equity Research

                  Alkermes (ALKS) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

                    by Zacks Equity Research

                    Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

                      Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View

                      by Zacks Equity Research

                      Alkermes' (ALKS) earnings beat estimates but sales lagged the same in the third quarter of 2017.

                        Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher

                        by Zacks Equity Research

                        Alkermes plc (ALKS) saw its shares rise over 11% on the day.

                          Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC

                          by Zacks Equity Research

                          The FDA slaps a refusal-to-file letter on Allergan's (AGN) Vraylar for its supplemental New Drug Application. The company tries to expand the drug???s label for its use as a maintenance treatment.

                            Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia

                            by Zacks Equity Research

                            Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.

                              Arpita Dutt headshot

                              Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe

                              by Arpita Dutt

                              Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.

                                Alkermes Initiates Rolling Submission of Depression Drug

                                by Zacks Equity Research

                                Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.

                                  Kevin Cook headshot

                                  What You See, and What You Get: The Neurology of Perception

                                  by Kevin Cook

                                  While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.

                                    Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat

                                    by Zacks Equity Research

                                    Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More

                                      by Arpita Dutt

                                      Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.

                                        Alkermes Presents Phase III Data on Schizophrenia Candidate

                                        by Zacks Equity Research

                                        Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.

                                          Minerva On Track to Initiate Phase III Schizophrenia Study

                                          by Zacks Equity Research

                                          Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.

                                            Alkermes Commences Phase III Study for Schizophrenia Drug

                                            by Zacks Equity Research

                                            Alkermes plc (ALKS) announced that it initiated a phase III study, ENLIGHTEN-Early on experimental candidate, ALKS 3831.

                                              Alkermes Gets FDA Nod for Two Month Dose of Aristada

                                              by Zacks Equity Research

                                              Alkermes plc (ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.

                                                Arpita Dutt headshot

                                                Key FDA Events to Watch Out for in Jun 2017

                                                by Arpita Dutt

                                                Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

                                                  Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue?

                                                  by Zacks Equity Research

                                                  Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.